Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1302 Trial
Conditions
Head and Neck Cancer
Conditions: official terms
Head and Neck Neoplasms
Conditions: Keywords
recurrent squamous cell carcinoma of the hypopharynx, stage IV squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, stage IVA squamous cell carcinoma of the larynx, stage IVB squamous cell carcinoma of the larynx, stage IVC squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, stage IVA squamous cell carcinoma of the lip and oral cavity, stage IVB squamous cell carcinoma of the lip and oral cavity, stage IVC squamous cell carcinoma of the lip and oral cavity, recurrent metastatic squamous neck cancer with occult primary, recurrent squamous cell carcinoma of the nasopharynx, stage IV squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, stage IVA squamous cell carcinoma of the oropharynx, stage IVB squamous cell carcinoma of the oropharynx, stage IVC squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity, stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity, stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent salivary gland cancer, stage IVA salivary gland cancer, stage IVB salivary gland cancer, stage IVC salivary gland cancer
Study Type
Observational
Study Phase
N/A
Study Design
N/A
Intervention
Name: mutation analysis Type: Genetic
Name: polymerase chain reaction Type: Genetic
Name: polymorphism analysis Type: Genetic
Name: laboratory biomarker analysis Type: Other
Overall Status
Not yet recruiting
Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This laboratory study is looking at biomarkers in samples from patients with recurrent or metastatic head and neck cancer treated on ECOG-E1302 trial.
Detailed Description
OBJECTIVES:

- To evaluate the frequency of ATP-binding cassette, sub-family G (WHITE), member 2 (ABCG2), met proto-oncogene (hepatocyte growth factor receptor) (c-MET), and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-ras) polymorphisms or mutations in this study population and the predictiveness of these polymorphisms on survival, time to progression, response rate, and toxicities.

OUTLINE: Archived tumor tissue and peripheral blood mononuclear cells are analyzed for the frequency of ABCG2, c-MET, and K-ras polymorphisms or mutations by polymerase chain reaction (PCR). Results are then correlated with patients' clinical outcomes and toxicity.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

- Patients diagnosed with recurrent or metastatic head and neck cancer treated on Eastern Cooperative Oncology Group (ECOG)-E1302 trial

- Patients treated with docetaxel with versus without gefitinib

- Existing paraffin blocks and peripheral blood mononuclear cells

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics
Location
Start Date
May 2012
Sponsors
Eastern Cooperative Oncology Group
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page